trending Market Intelligence /marketintelligence/en/news-insights/trending/IoINxSDgDGaonD-0h5esOw2 content esgSubNav
In This List

Eisai insomnia drug Dayvigo wins US FDA approval

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Eisai insomnia drug Dayvigo wins US FDA approval

Eisai Co. Ltd. said the U.S. Food and Drug Administration approved its drug Dayvigo for treating insomnia in adults.

The Tokyo-based drugmaker said the U.S. regulator gave the nod to Dayvigo, or lemborexant, as a therapy for insomnia characterized by difficulties with sleep onset and maintenance. Insomnia is the most common sleep disorder, affecting 30% of the adult population globally.

Lemborexant works by acting on the orexin neurotransmitter system, which regulates a person's wakefulness. Eisai was previously collaborating with Purdue Pharma LP on the medicine, but the Japanese company took over sole development of the drug in May after the latter became embroiled in a series of lawsuits over the U.S. opioid epidemic.

Eisai's application for Dayvigo was based on the results of two phase 3 trials called Sunrise 1 and Sunrise 2, which enrolled about 2,000 patients.

Eisai is also seeking Japanese and Canadian approval for Dayvigo.